OSE’s Tedopi-Keytruda Combo Clears Phase II Ovarian Cancer Hurdle

Why It Matters

The data show a therapeutic vaccine can amplify checkpoint blockade in a disease where immunotherapy has struggled, creating a potential new maintenance option and attracting investor interest. Success could expand immunotherapy beyond chemotherapy‑based combos, reshaping treatment pathways for ovarian cancer.

Key Takeaways

• Tedopi‑Keytruda combo extended PFS to 4.1 months versus 2.8 months
• Risk of progression or death fell 28% when adding Keytruda to Tedopi
• Study focused on patients post‑PARP inhibitor and bevacizumab therapy
• OSE plans Phase III lung cancer trial while expanding vaccine combos

Pulse Analysis

Ovarian cancer remains one of the most resistant solid tumours to immunotherapy, with single‑agent PD‑1 inhibitors delivering modest benefits. The TEDOVA trial addressed this gap by testing a maintenance strategy that pairs a therapeutic vaccine with checkpoint blockade after patients have exhausted PARP inhibitors and bevacizumab. By enrolling 185 platinum‑sensitive, HLA‑A2‑positive patients, the study provided a clear comparator against best supportive care, highlighting a measurable progression‑free survival advantage that could translate into longer disease control.

Tedopi (OSE2101) is an off‑the‑shelf, epitope‑based vaccine targeting five tumour‑associated antigens to prime tumour‑specific T‑cells. When combined with Keytruda, the vaccine’s ability to generate a robust T‑cell response is protected from PD‑1‑mediated exhaustion, explaining the observed 28% reduction in progression risk. Although the combination generated more immune‑related adverse events, these align with known checkpoint inhibitor profiles and did not outweigh the efficacy signal. This mechanistic synergy suggests that vaccines may serve as effective partners for checkpoint inhibitors in maintenance settings, where the tumour burden is low and immune activation can be sustained.

For OSE, the positive Phase II readout strengthens its valuation and supports a diversified pipeline that includes a Phase III ARTEMIA trial in HLA‑A2‑positive non‑small cell lung cancer resistant to prior immunotherapy. The data also position OSE to attract collaborations for vaccine‑checkpoint combos across pancreatic and other solid tumours. If subsequent trials confirm durable overall survival benefits, the Tedopi‑Keytruda regimen could become a new standard of care, prompting payers and clinicians to reconsider maintenance strategies in ovarian cancer and potentially unlocking a broader market for off‑the‑shelf cancer vaccines.